| Number: 201104047 |
Principal Investigator: Thaker, Premal |
| Title: Feasibility Study: Therapeutic Targeting of Stress Factors in Ovarian Cancer Patients |
| Description: This research is looking at the effect of biobehavioral factors such as stress and whether these factors alter how the body responds to chemotherapy. One of the purposes of this study is to determine if the addition of a beta-blocker such as Propranolol (Inderal) is tolerable when given with chemot...MORE |
| ___________________________________________________________________________________________________ |
| Number: GOG 9924 |
Principal Investigator: Mutch, David |
| Title: A Phase I Pharmacokinetic Study of Intraperitoneal CTEP-Supplied Agent Bortezomib and Carboplatin in Patients with Persistent or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
| Description: The purpose of this study is to see what dose of the anti-cancer drug bortezomib can be given with carboplatin in the treatment of your cancer. We will check this by giving this drug and carboplatin, another anti-cancer drug, directly into your abdomen. One of the goals of this study is to determi...MORE |
| ___________________________________________________________________________________________________ |
| Number: GOG 9923 |
Principal Investigator: Mutch, David |
| Title: A Phase I Study of Carboplatin/Paclitaxel/CTEP-Supplied Agent Bevacizumab and CTEP-Supplied Agent ABT-888 in Newly Diagnosed Patients with Previously Untreated Eipthelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer |
| Description: One of the purposes of this study is to test the safety of ABT-888 at different dose levels. It will be given with standard initial chemotherapy as well as a drug called bevacizumab. Standard chemotherapy for your type of cancer usually consists of two drugs called carboplatin and paclitaxel. Ano...MORE |
| ___________________________________________________________________________________________________ |
| Number: GOG 264 |
Principal Investigator: Mutch, David |
| Title: A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin Etoposide, and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemonaive Sex Cord-Stromal Tumors of the Ovary |
| Description: The purpose of this study is to find out whether treatment with drugs paclitaxel and carboplatin work better to control your cancer than treatment with the drugs bleomycin, etoposide and cisplatin, which is the standard treatment for your type of cancer. Another purpose of this study is to find out...MORE |
| ___________________________________________________________________________________________________ |
| Number: GOG 213 |
Principal Investigator: Mutch, David |
| Title: A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel Alone or in Combination with Bevacizumab Followed By Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer |
| Description: Standard treatment for your type of cancer usually consists of two chemotherapy drugs, carboplatin and paclitaxel, which are given every three weeks for a total of six treatments. Chemotherapy is given to control the growth of your cancer and to lower the chance of it coming back. Treatment with c...MORE |
| ___________________________________________________________________________________________________ |
| Number: GOG 0260 |
Principal Investigator: Mutch, David |
| Title: A Phase II Evaluation of Elesclomol Sodium and Weekly Paclitaxel in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer |
| Description: You are being asked to take part in this study because you have ovarian, fallopian tube, or primary peritoneal cancer that has failed to respond to initial chemotherapies given to you or has re-grown after surgery, radiation therapy, or other forms of therapy.
The purpose of this study is to find o...MORE |
| ___________________________________________________________________________________________________ |
| Number: GOG 0254 |
Principal Investigator: Mutch, David |
| Title: A Phase II Evaluation of SU11248 (Sunitinib Malate) In the Treatment of Persistent or Recurrent Clear Cell Ovarian Carcinoma |
| Description: The purpose of this study is to find out if SU11248 (sunitinib malate) works in treating your type of cancer and to find out what side effects are caused by treatment with this drug. Sunitinib has been approved by the Food and Drug Administration (FDA) for the treatment of a type of stomach cancer ...MORE |
| ___________________________________________________________________________________________________ |
| Number: GOG 0241 |
Principal Investigator: Mutch, David |
| Title: A GCIG Intergroup Multicenter Phase III Trial of Open Label Carboplatin and Paclitaxel +/- NCI Supplied Agent: Bevacizumab (NSC #704865, IND #7921) Compared with Oxaliplatin and Capecitabine +/- Bevacizumab as First Line Chemotherapy in Patients with Mucinous Epithelial Ovarian Cancer or Fallopian Tube Cancer |
| Description: The purpose of this study is to compare the effects of several different treatments to find out which works better to control your cancer. In this study, you will receive one of the following treatments: 1) oxaliplatin and capecitabine; 2) standard treatment with carboplatin and paclitaxel; 3) the c...MORE |
| ___________________________________________________________________________________________________ |
| Number: GOG 0212 |
Principal Investigator: Mutch, David |
| Title: A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12 Monthly Cycles of Single Agent Paclitaxel or XYOTAX, Versus No Treatment Until Documented Relapse in Women with Advanced Ovarian or Primary Peritoneal Cancer Achieve A Complete Clinical Response to Primary Platinum/Taxane Chemotherapy |
| Description: Primary peritoneal and fallopian tube cancers are considered identical to ovarian cancers in terms of microscopic appearance and treatment; they differ only by the initial body site of cancer development. A previously completed study showed that women with advanced ovarian cancer who had no sign of...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201206062 |
Principal Investigator: Mutch, David |
| Title: A Randomized, Double Blind, Placebo-Controlled Phase 1b/2 Study of LY2228820, a p38 MAPK Inhibitor, plus Gemcitabine and Carboplatin versus Gemcitabine and Carboplatin for Women with Platinum-Sensitive Ovarian Cancer (Ver 1/11/12) |
| Description: This study is being done to see how safe an investigational drug (LY2228820) is and how well it will work to help people with ovarian cancer, fallopian tube cancer or primary peritoneal cancer....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201201081 |
Principal Investigator: Mutch, David |
| Title: A Randomized Double-Blind Phase 3 Trial Comparing EC145 and Pegylated Liposomal Doxorubicin (PLD/Doxil/Caelyx) in Combination versus PLD in Participants with Platinum-Resistant Ovarian Cancer |
| Description: The purpose of this study is to test the effects of EC145 in combination with Doxil®/Caelyx® good or bad, in women with platinum-resistant ovarian cancer. We also want to test the safety of EC145 in combination with Doxil®/Caelyx®....MORE |
| ___________________________________________________________________________________________________ |
| Number: GOG 0235 |
Principal Investigator: Mutch, David |
| Title: A Prospective, Longitudinal Study of YKL-40 in Patients with FIGO Stage III or IV Invasive Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer undergoing Primary Chemotherapy |
| Description: The purpose of this study is to evaluate a new test that measures YKL-40 to see if the amount of YKL-40 in your blood can help us monitor ovarian cancer. YKL-40 is a protein that is found when certain pathologic conditions are present. The exact function of this protein is currently not known. Sp...MORE |
| ___________________________________________________________________________________________________ |
| Number: GOG 0273 |
Principal Investigator: Mutch, David |
| Title: Chemotherapy Toxicity in Elderly Women with Ovarian, Primary Peritoneal or Fallopian Tube Cancer |
| Description: You are being asked to take part in this study because you have a confirmed diagnosis of ovarian, primary peritoneal, or fallopian tube cancer, you have not been previously been treated for this cancer, you are age 70 or older, and you and your physician have decided that either single-agent carbopl...MORE |
| ___________________________________________________________________________________________________ |
| Number: GOG 0267 |
Principal Investigator: Mutch, David |
| Title: Quality of Life and Care Needs In Patients With Persistent Or Recurrent Platinum-Resistant Ovarian, Fallopian Tube, And Peritoneal Cancer |
| Description: The purpose of this study is to assess the quality of life and needs of women with advanced ovarian cancer, fallopian tube, or peritoneal cancer, as well as the support available to them. The study will look at how patients’ symptoms and needs affect their health and their quality of life. If you ar...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201210087 |
Principal Investigator: Novetsky, Akiva |
| Title: Etiology of fever in non-operative gynecologic oncology patients |
| ___________________________________________________________________________________________________ |
| Number: 201105400 |
Principal Investigator: Mutch, David |
| Title: Formation of a Tissue Bank for Gynecologic Malignancies |
| Description: The purpose of this study is to collect specimens (i.e., tissue obtained during surgery and/or blood) and related information from women who are undergoing surgery for a gynecologic condition. Specimens and related information that are collected for this research study will be used for future cance...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201104186 |
Principal Investigator: Jungheim, Emily |
| Title: Ovarian Tissue Freezing for Fertility Preservation in Women Facing a Fertility Threatening Medical Diagnosis or Treatment Regimen |
| ___________________________________________________________________________________________________ |
| Number: 201104242 |
Principal Investigator: Thaker, Premal |
| Title: Biobehavioral Influences and the Ovarian Tumor Microenvironment |
| Description: The purpose of this study is to understand relationships between behavioral factors, hormones, and chemicals produced by the body that may help tumor growth in ovarian cancer. The significance of this research is that it may help in our understanding of risk factors for progression of ovarian cance...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201209132 |
Principal Investigator: Kizer, Nora |
| Title: Effect of Hormonal Treatment on Outcomes in Women with Ovarian Borderline Tumors |
| ___________________________________________________________________________________________________ |
| Number: 201207145 |
Principal Investigator: Apicelli, Anthony |
| Title: Retrospective Dosimetric and Outcomes Analysis of Intensity Modulated Radiation Therapy as Salvage for Localized Recurrent Ovarian Cancer |
| ___________________________________________________________________________________________________ |
| Number: 201202115 |
Principal Investigator: Novetsky, Akiva |
| Title: Outcomes of patients with ovarian, primary peritoneal and fallopian tube cancer secondary to shortage of liposomal doxorubicin (Doxil) |
| ___________________________________________________________________________________________________ |
| Number: 201109305 |
Principal Investigator: Garg, Gunjal |
| Title: The Impact of Conservative vs. Surgical Management on Survival of Gynecologic Oncology Patients Diagnosed with Intestinal Perforation |
| ___________________________________________________________________________________________________ |
| Number: 201108327 |
Principal Investigator: Wang-Gillam, Andrea |
| Title: Phase I Study of Erlotinib and Temsirolimus in Resistant Solid Malignancies |
| Description: The purpose of this study is to determine the maximum tolerated dose and side effects of the combination of two drugs, temsirolimus and erlotinib, used to treat solid tumor cancers. Temsirolimus is approved by the Food and Drug Administration (FDA) for treatment of renal cancer and is considered inv...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201107068 |
Principal Investigator: Lockhart, A. Craig |
| Title: Phase I Safety and Pharmacokinetic Study of XRP6258 (Cabazitaxel) In Advanced Solid Tumor Patients with Varying Degrees of Hepatic Impairment |
| Description: The purpose of this study is to determine if Cabazitaxel is a safe treatment for patients with advanced cancers of different types who also have different levels of liver dysfunction. The highest safe dose of cabazitaxel (the maximum tolerated dose, or MTD) that can be given to patients with your le...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201102468 |
Principal Investigator: Lockhart, A. Craig |
| Title: An Open-Label Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 When Administered as a Single Agent in Patients With
Advanced or Metastatic Solid Tumors |
| Description: There are two parts to this research study. The purpose of Part 1 is to find out the highest safe dose of the investigational drug CEP-9722. “Investigational” means that the study drug has not been approved by the United States Food & Drug Administration (F.D.A). Part 2 of the study is to find out m...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201102462 |
Principal Investigator: Lockhart, A. Craig |
| Title: A Phase 1b, Multi-Center, Open Label, Uncontrolled, Serial Cohort, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Daily Oral Doses of ZSTK474 in Subjects with Advanced Solid Malignancies |
| Description: The main purpose of this study is to find out if the drug ZSTK474 is safe in people who have advanced cancers.
ZSTK474 is an investigational (experimental) drug. This means it has not been approved by the Food and Drug Administration (FDA). It is not currently on the market in any country. This stu...MORE |
| ___________________________________________________________________________________________________ |